BioCentury
ARTICLE | Clinical News

RSV F vaccine: Phase III data

September 26, 2016 7:00 AM UTC

Top-line data from the observer-blind, U.S. Phase III Resolve trial in 11,856 adults ages >=60 showed that a single dose of 135 ug intramuscular RSV F vaccine missed the primary endpoint of reducing t...